The Royal Bournemouth Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
19 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kerr, David J
NCT04938388: Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Terminated
4
12
US
Semaglutide Pill, Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide 14 mg, Fresh organic vegetables
Sansum Diabetes Research Institute, Novo Nordisk A/S
Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
02/23
02/23
CHAT, NCT05293340: Continuous Glucose Monitoring and Hass Avocado Trial ("")

Terminated
N/A
50
US
Avocado Vouchers
Sansum Diabetes Research Institute, Hass Avocado Board
Dietary Habits, Diabetes Mellitus, Type 2
01/23
01/23
NCT05368454: Evaluation of a Digital Diabetes Self-Management Education and Support Program

Completed
N/A
100
US
Online Diabetes Self-Management Education and Support (DSMES) Program, Standard of Care
Omada Health, Inc., Abbott Diabetes Care, Evidation Health
Type 2 Diabetes
01/24
01/24
NCT05000840: Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA

Recruiting
N/A
750
US
Enrollment in existing SDRI diabetes education programs
Sansum Diabetes Research Institute, Abbott, DexCom, Inc.
Diabetes Mellitus, Type 2, Cardiovascular Diseases
07/24
12/24
NCT04991142: Models of Nutrition From Continuous Glucose Monitors

Completed
N/A
45
US
Texas A&M University, Sansum Diabetes Research Institute
Diabetes Mellitus, Type 2, Pre-diabetes, Diet Habit, Diet, Healthy
08/24
08/24
Hickish, Tamas
PRIMUS 001, NCT04151277 / ISRCTN75002153 / 2016-004155-67: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

Recruiting
2
500
Europe
FOLFOX-A, Gemcitabe and Abraxane, G-CSF
Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow
Neoplasms Pancreatic
12/25
01/26
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Recruiting
N/A
2500
Europe
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde
Neoplasms Pancreatic
12/25
12/25
Middleton, Robert
NCT02126345: MASTER SL Clinical Study

Active, not recruiting
N/A
150
Europe
MASTER SL femoral stem and DELTA TT acetabular cup
Limacorporate S.p.a
Patients Requiring Hip Replacement
12/21
12/23
NCT06744582: Estimating VO2 Max and Recovery

Not yet recruiting
N/A
30
Europe
VO2 max
Bournemouth University, Nuffield Health Bournemouth
Hip Osteoarthritis
04/26
04/26
NCT04754087: G7 Acetabular System with Vivacit-E or Longevity Liner PMCF Study

Recruiting
N/A
300
Europe, US
Vivacit-E and Longevity (HXLPE) Liners
Zimmer Biomet
Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
12/33
12/33
Bent, Clare
NCT04941924: The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction.

Recruiting
N/A
24
Europe
Intraductal Radio-Frequency Ablation, Biliary Stent Placement
University Hospitals Dorset NHS Foundation Trust, The Christie NHS Foundation Trust
Malignant Biliary Obstruction
10/23
10/23
Thavanesan, Kamy
ENRICH-AF, NCT03950076 / 2019-002075-33: EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation

Active, not recruiting
4
948
Europe, Canada, US, RoW
Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy
Population Health Research Institute
Intracranial Hemorrhages, Atrial Fibrillation
04/26
10/26
OPTIMAS, NCT03759938: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

Active, not recruiting
N/A
3648
Europe
Direct oral anticoagulant (DOAC), dabigatran, apixaban, edoxaban, rivaroxaban
University College, London
Stroke, Acute, Atrial Fibrillation
05/24
10/24
NCT05476913: GEKO Venous Thromboembolism Prevention Study

Recruiting
N/A
1200
Europe
geko™ device, geko, NMES
Firstkind Ltd, National Institute for Health Research, United Kingdom, Keele University, University Hospitals of North Midlands NHS Trust, University of California, Bournemouth University
Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
04/25
06/25
Azim, Abul
PROHIBIT-ICH, NCT03863665: Prevention of Hypertensive Injury to the Brain by Intensive Treatment of Blood Pressure After Intracerebral Haemorrhage

Terminated
N/A
86
Europe
A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci
University College, London, University of Oxford, The Stroke Association, United Kingdom
Intracerebral Hemorrhage
05/22
04/23
OPTIMAS, NCT03759938: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

Active, not recruiting
N/A
3648
Europe
Direct oral anticoagulant (DOAC), dabigatran, apixaban, edoxaban, rivaroxaban
University College, London
Stroke, Acute, Atrial Fibrillation
05/24
10/24
NCT05476913: GEKO Venous Thromboembolism Prevention Study

Recruiting
N/A
1200
Europe
geko™ device, geko, NMES
Firstkind Ltd, National Institute for Health Research, United Kingdom, Keele University, University Hospitals of North Midlands NHS Trust, University of California, Bournemouth University
Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
04/25
06/25
Araque, Paloma Rodríguez
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27

Download Options